GHENT, BELGIUM--(Marketwire - April 27, 2012) - REGULATED INFORMATION
GHENT, Belgium, 27 April 2012 - Ablynx (EURONEXT BRUSSELS: ABLX)
announced, in accordance with Article 14 of the Belgian Law of 2 May
regarding the publication of major shareholdings in issuers whose
admitted to trading on a regulated market (the "Transparency Law"),
received a notification of shareholdings from vzw VIB.
The above shareholder now owns less than 3% in Ablynx.
Full versions of all transparency notifications are available on the
Ablynx, section Investors.
Ablynx is a biopharmaceutical company engaged in the discovery and
of Nanobodies(®), a novel class of therapeutic proteins based on
antibody fragments, for a range of serious and life-threatening human
including inflammation, haematology, oncology and pulmonary disease.
Company has over 25 programmes in the pipeline and seven Nanobodies at
development stage. Ablynx has ongoing research collaborations and
partnerships with major pharmaceutical companies, including
Ingelheim, Merck Serono and Novartis. The Company is headquartered in
Belgium. More information can be found on www.ablynx.com.
Complete version of the press release:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Ablynx via Thomson Reuters ONE